Find Reports

Select Report Type

Reimbursement Review

Displaying 401 - 425 of 1426

Please scroll or swipe to the right to view the full content.

Title	Brand Name	Generic Name	Files	Therapeutic Area	Recommendation Type	Status	Submission Date	Recommendation Date Sort ascending	Project Number
Niraparib (Zejula) for Ovarian...	Zejula	Niraparib	10203NiraparibOC_fnRec_pERC Chair Approved_Post_03Sep2020_final.pdf 10203NiraparibOC_fnEGR_REDACTABBREV_Post03Sep2020_final.pdf 10203NiraparibOC_fnCGR_REDACT_Post_03Sep2020_final.pdf 10203NiraparibOC_InitialRec_Approved_03Jul2020_final.pdf 10203NiraparibOC_PAGFeedbackSummary_Post03Sep2020_final.pdf 10203NiraparibOC_SponsorFeedback_2020-17-07_Post03Sep2020_final_Redacted.pdf 10203NiraparibOC_PatientFeedback_OCC_2020-14-07_Post03Sep2020_final.pdf 10203NiraparibOC_ClinicianFeedback_CCO_2020-17-07_Post03Sep2020_final_Redacted.pdf 10203NiraparibOC_PatientInput_OCC_2020-02-24_revised_Post03Sep2020_final.pdf 10203NiraparibOC_CombinedClinician COIs_Post03Sep2020_final_Redacted.pdf	Ovarian Cancer	Reimburse with clinical criteria and/or conditions	Complete	Feb 7, 2020	Sep 3, 2020	PC0203-000
caplacizumab	Cablivi	caplacizumab	SR0633 Cablivi - CDEC Final Recommendation September 1, 2020 for posting.pdf sr0633-cablivi-clinical-review-report.pdf sr0633-cablivi-pharmacoeconomic-review-report.pdf Cablivi - Patient Group Input for posting.pdf	Acquired thrombotic thrombocytopenic purpura (aTTP)	Do not reimburse	Complete	Sep 13, 2019	Aug 26, 2020	SR0633-000
eculizumab	Soliris	eculizumab	SR0640 Soliris - CDEC Final Recommendation August 24, 2020 for posting.pdf sr0640-soliris-nmosd-clinical-review-report.pdf sr0640-soliris-nmosd-pharmacoeconomic-review-report.pdf SR0640_Soliris NMOSD_PI Submission.pdf	Neuromyelitis optica spectrum disorder	Reimburse with clinical criteria and/or conditions	Complete	Feb 25, 2020	Aug 19, 2020	SR0640-000
erenumab	Aimovig	erenumab	SR0578 Aimovig - CDEC Final Recommendation July 24, 2020 (redacted)_For Posting.pdf sr0578-aimovig-clinical-review-report.pdf sr0578-aimovig-pharmacoeconomic-review-report.pdf SR0578-Aimovig-patient-input.pdf	Migraine	Reimburse with clinical criteria and/or conditions	Complete	May 2, 2019	Jul 22, 2020	SR0578-000
cabotegravir/rilpivirine	Vocabria and Cabenuva	cabotegravir sodium cabotegravir-rilpivirine	SR0628 Vocabria + Cabenuva - Final CDEC Recommendation September 9, 2020_for posting.pdf SR0628 cabotegravir + rilpivirne - Group Patient Input_October 21, 2019.pdf sr0628-vocabria+cabenuva-clinical-review-report-QC_redacted-gg.pdf sr0628-vocabria+cabenuva-pharmacoeconomic-review-report.pdf	HIV-1 infection	Reimburse with clinical criteria and/or conditions	Complete	Aug 19, 2019	Jul 22, 2020	SR0628-000
siponimod	Mayzent	siponimod	SR0631_Mayzent_PI Submission.pdf SR0631 Mayzent - CDEC Final Recommendation July 23, 2020 (redacted)_For posting.pdf sr0631-mayzent-clinical-review-report.pdf sr0631-mayzent-pharmacoeconomic-review-report.pdf	Secondary progressive multiple sclerosis	Reimburse with clinical criteria and/or conditions	Complete	Sep 26, 2019	Jul 21, 2020	SR0631-000
icosapent ethyl	Vascepa	icosapent ethyl	SR0619 Vascepa - CDEC Final Recommendation July 20, 2020_for posting.pdf sr0619-vascepa-clinical-review-report.pdf sr0619-vascepa-pharmacoeconomic-review-report.pdf	Ischemic events in statin-treated patients	Reimburse with clinical criteria and/or conditions	Complete	Jun 17, 2019	Jul 16, 2020	SR0619-000
ustekinumab	Stelara/Stelara I.V	ustekinumab	SR0627_Stelara UC_PI Submission.pdf SR0627 Stelara - CDEC Final Recommendation July 20, 2020_for posting.pdf sr0627-stelara-clinical-review-report.pdf sr0627-stelara-pharmacoeconomic-review-report.pdf	Ulcerative colitis	Reimburse with clinical criteria and/or conditions	Complete	Aug 12, 2019	Jul 16, 2020	SR0627-000
Tecentriq & Avastin Non-Sq...	Tecentriq & Avastin	Atezolizumab & Bevacizumab	10155AtezolizumabBevacizumabNSQ-NSCLC_FinalRec_Post03July2020_final_Redacted.pdf 10155AtezolizumabBevacizumabNSQ-NSCLC_fnEGR_REDACT-ABBREV_Post03Jul2020_final.pdf 10155AtezolizumabBevacizumabNSQ-NSCLC_fnCGR_REDACT_Post03Jul2020_final.pdf 10155AtezolizumabBevacizumabNSQ-NSCLC_inRec_REDACT_pERC Chair Approved_Post30Apr2020_final.pdf 10155AtezolizumabBevacizumabNSQ-NSCLC_PAGFeedbackSummary_Post03Jul2020_final.pdf 10155AtezolizumabBevacizumabNSQ-NSCLC_SponsorFeedback_Post03Jul2020_final_Redacted.pdf 10155AtezolizumabBevacizumabNSQ-NSCLC_PatientFeedback_Post03Jul2020_final.pdf 10155AtezolizumabBevacizumabNSQ-NSCLC_Combined ClinicianFeedback_Post03Jul2020_final_Redacted.pdf 10155AtezolizumabBevacizumabNSQ-NSCLC_COI_LCC_Post03Jul2020_final.pdf 10155AtezolizumabBevacizumabNSQ-NSCLC_Combined COIs_Post03Jul2020_final_Redacted.pdf	NSQ-NSCLC	Do not reimburse	Complete	Nov 18, 2019	Jul 3, 2020	PC0155-000
glycopyrrolate	Cuvposa	glycopyrrolate	SR0613 Cuvposa - CDEC Final Recommendation June 26, 2020_for posting.pdf sr0613-cuvposa-pharmacoeconomic-review-report.pdf sr0613-cuvposa-clinical-review-report.pdf	chronic severe drooling, neurologic (pediatric)	Do not reimburse	Complete	May 31, 2019	Jun 24, 2020	SR0613-000
Kisqali for Advanced or Metast...	Kisqali	Ribociclib	RibociclibKisqali_MBC10194ProvFunding.pdf 10194RibociclibMBC_FnRec_Chair Approved_Post04Jun2020_final.pdf 10194RibociclibMBC_fnEGR_NOREDACT-ABBREV_Post04Jun2020_final.pdf 10194RibociclibMBC_fnCGR_NOREDACT_Post04Jun2020_final.pdf 10194RibociclibMBC_inRec_pERC Chair Approved_Post02Apr2020_final.pdf 10194RibociclibMBC_PAGFeedbackSummary_Post04Jun2020_final.pdf 10194RibociclibMBC_SponsorFeedback_Post04Jun2020_final.pdf 10194RibociclibMBC_Combined_PatientFeedback_Post04Jun2020_final_Redacted.pdf 10194RibociclibMBC_ClinicianFeedback_CCO_Post04Jun2020_final_Redacted.pdf 10194RibociclibMBC_Combined COI_Redacted.pdf 10194RibociclibMBC_Clinician Combined COI_Redacted.pdf	HR+, HER2- advanced or metastatic breast cancer	Reimburse with clinical criteria and/or conditions	Complete	Aug 26, 2019	Jun 4, 2020	PC0194-000
Brentuximab Vedotin (Adcetris)...	Adcetris	Brentuximab Vedotin	BrentuximabVedotinAdcetris_PTCL10199ProvFunding.pdf 10199BrentuximabVedotinPTCL_FnRec_approved_Post04Jun2020_final.pdf 10199BrentuximabVedotinPTCL_fnEGR_NOREDACT-ABBREV_Post04Jun2020_final.pdf 10199BrentuximabVedotinPTCL_fnCGR_NOREDACT_Post04Jun2020_final.pdf 10199BrentuximabVedotinPTCL_inRec_approvedbyChair_NOREDACT_Post02Apr2020_final.pdf 10199BrentuximabVedotinPTCL_PAGFeedbackSummary_Post04Jun2020_final.pdf 10199BrentuximabVedotinPTCL_SponsorFeedback_Post04Jun2020_final_Redacted.pdf 10199BrentuximabVedotinPTCL_PatientFeedback_LC_Post04Jun2020_final.pdf 10199BrentuximabVedotinPTCL_ClinicianFeedback_CCO_Post02Jun2020_final_Redacted.pdf 10199BrentuximabVedotinPTCL_Patient_COI_LC_Post04Jun2020_final.pdf 10199BrentuximabVedotinPTCL_Combined_Clinician_COIs_Post04Jun2020_final_Redacted.pdf	peripheral T-cell lymphoma (PTCL)	Reimburse	Complete	Oct 8, 2019	Jun 4, 2020	PC0199-000
naltrexone hydrochloride and b...	Contrave	naltrexone hydrochloride and bupropion hydrochloride	SR0610 Contrave - CDEC Final Recommendation June 5, 2020 Final_for posting.pdf sr0610-contrave-clinical-review-report.pdf sr0610-contrave-pharmacoeconomic-review-report.pdf SR0610 Contrave - Patient Group Input June 17, 2019.pdf	Chronic weight management in adults	Do not reimburse	Complete	May 1, 2019	May 27, 2020	SR0610-000
burosumab	Crysvita	burosumab	SR0602 Crysvita - CDEC Final Recommendation May 29, 2020_For posting.pdf sr0602-crysvita-clinical-review-report.pdf sr0602-crysvita-pharmacoeconomic-review-report.pdf Crysvita - Patient Group Input - For posting.pdf	Treatment of X-Linked Hypophosphatemia	Reimburse with clinical criteria and/or conditions	Complete	Jul 23, 2019	May 27, 2020	SR0602-000
brolucizumab	Beovu	brolucizumab	SR0632 Beovu - CDEC Final Recommendation – May 25, 2020_for posting.pdf sr0632-beovu-clinical-review-report.pdf sr0632-beovu-pharmacoeconomic-review-report.pdf SR0632_Brolucizumab_PI Submission.pdf	Macular degeneration, age-related	Reimburse with clinical criteria and/or conditions	Complete	Sep 26, 2019	May 21, 2020	SR0632-000
Gilteritinib (Xospata) for Acu...	Xospata	Gilteritinib	GilteritinibXospata__AML10102_ProvFunding.pdf 10202GilteritinibAML_FnRec_REDACT_EarlyConv_20May2020_final.pdf 10202GilteritinibAML_fnCGR_REDACT_EarlyConv_20May2020_final.pdf 10202GilteritinibAML_fnEGR_REDACT-ABBREV_EarlyConv20May2020_final.pdf 10202GilteritinibAML_inRec_REDACT_ApprovedbyChair_Post30Apr2020_final.pdf 10202GilteritinibAML_PAGFeedbackSummary_Post20May2020_final.pdf 10202GilteritinibAML_SponsorFeedback_Post20May2020_final.pdf 10202GilteritinibAML_PatientFeedback_LLSC_Post20May2020_final_Redacted.pdf 10202GilteritinibAML_ClinicianFeedback_CCODAC_Post20May2020_final.pdf 10202GilteritinibAML_COI-LLSC_Post20May2020_final.pdf 10202GilteritinibAML_Combined_ClincianInput_Post20May2020_final_Redacted.pdf		Reimburse with clinical criteria and/or conditions	Complete	Oct 28, 2019	May 20, 2020	PC0202 -000
vedolizumab	Entyvio	vedolizumab	SR0635 Entyvio - CDEC Final Recommendation – May 21, 2020_for posting.pdf sr0635-entyvio-clinical-review-report.pdf sr0635-entyvio-pharmacoeconomic-review-report.pdf SR0635_Entyvio_PI Submission.pdf	Ulcerative Colitis	Reimburse with clinical criteria and/or conditions	Complete	Nov 21, 2019	May 19, 2020	SR0635-000
belimumab	Benlysta	Belimumab	SR0616 Benlysta - CDEC Final Recommendation April 24, 2020_For Posting.pdf sr0616-benlysta-clinical-review-report.pdf sr0616-benlysta-pharmacoeconomic-review-report.pdf SR0616_Benlysta_PI Submission1.pdf	systemic lupus erythematosus	Do not reimburse	Complete	May 29, 2019	Apr 22, 2020	SR0616-000
Kisqali (with Fulvestrant) for...	Kisqali	Ribociclib with Fulvestrant	RibociclibKisqali+Fulvestrant_MBC10195ProvFunding.pdf 10195RibociclibFulvestrantMBC_fnRec_pERC Chair Approved_22April2020_final.pdf 10195RibociclibFulvestrantMBC_fnEGR_NOREDACT-ABBREV_EC_22Apr2020_final.pdf 10195RibociclibFulvestrantMBC_fnCGR_NOREDACT_EC_22Apr2020_final.pdf 10195RibociclibFulvestrantMBC_inRec_pERC Chair Approved_Post02Apr2020_final.pdf 10195RibociclibFulvestrantMBC_PAGFeedbackSummary__EC_22Apr2020_final.pdf 10195RibociclibFulvestrantMBC_SponsorFeedback_EC_22Apr2020_final.pdf 10195RibociclibFulvestrantMBC_Combined_PatientFeedback.pdf 10195RibociclibFulvestrantMBC_ClinicianFeedback_CCO_EC_22Apr2020_final.pdf 10195RibociclibFulvestrantMBC_Combined COIs_EC_22Apr2020_final_Redacted.pdf 10195RibociclibFulvestrantMBC_Combined Clinician COI_EC_22Apr2020_final_Redacted.pdf	+Fulvestrant for HR+, HER2- advanced or metastatic breast cancer	Reimburse with clinical criteria and/or conditions	Complete	Aug 26, 2019	Apr 22, 2020	PC0195-000
Darolutamide (Nubeqa) for Non-...	Nubeqa	Darolutamide	10196DarolutamidenmCRPC_fnRec_REDACT_EC_22Apr2020_final.pdf 10196DarolutamidenmCRPC_fnEGR_REDACT-ABBREV_EC_22Apr2020_final.pdf 10196DarolutamidenmCRPC_fnCGR_REDACT_EC_22Apr2020_final.pdf 10196DarolutamidenmCRPC_inRec_approvedbyChair_REDACT_Post02Apr2020_final.pdf 10196DarolutamidenmCRPC_PAGFeedbackSummary_EC_22Apr2020_final.pdf 10196DarolutamidenmCRPC_SponsorFeedback_EC_22Apr2020_final.pdf 10196DarolutamidenmCRPC_ClinicianFeedback_CCO_EC_22Apr2020_final.pdf 10196DarolutamidenmCRPC_COI_CCSN__EC_22Apr2020_final.pdf 10196DarolutamidenmCRPC_Combined COI_EC_22Apr2020_final_Redacted.pdf	non-metastatic castration resistant prostate cancer (nmCRPC)	Reimburse with clinical criteria and/or conditions	Complete	Aug 27, 2019	Apr 22, 2020	PC0196-000
Apalutamide (Erleada) for Meta...	Erleada	Apalutamide	ApalutamideErleada_mCSPC10200ProvFunding.pdf 10200ApalutamidemCSPC_fnRec_ChairApproved_EarlyConv_22Apr2020_final.pdf 10200ApalutamidemCSPC_fnEGR_REDACT-ABBREV_EC_22Apr2020_final.pdf 10200ApalutamidemCSPC_fnCGR_REDACT__EC_22Apr2020_final.pdf 10200ApalutamidemCSPC_inRec_ApprovedbyChair_Post02Apr2020_final-updated.pdf 10200ApalutamidemCSPC_PAGFeedbackSummary_EC_22Apr2020_final.pdf 10200ApalutamidemCSPC_SponsorFeedback_EC_22Apr2020_final.pdf 10200ApalutamidemCSPC_ClinicianFeedback_CCO_EC_22Apr2020_final.pdf 10200ApalutamidemCSPC COICCSN_EC_22Apr2020_final.pdf 10200ApalutamidemCSPC_COI_Combined_Clinician Redacted.pdf	metastatic castration-sensitive prostate cancer (mCSPC)	Reimburse with clinical criteria and/or conditions	Complete	Oct 15, 2019	Apr 22, 2020	PC0200-000
Cabozantinib (Cabometyx) for H...	Cabometyx	Cabozantinib	10186CabozantinibHCC_FnRec_EC_22Apr2020_final.pdf 10186CabozantinibHCC_fnEGR_NOREDACT-ABBREV_EC_22Apr2020_final.pdf 10186CabozantinibHCC_inCGR_NOREDACT_EC_22Apr2020_final.pdf 10186CabozantinibHCC_inRec_2020-04-01_ApprovedbyChair_Post02Apr2020_final.pdf 10186CabozantinibHCC_PAGFeedbackSummary_EC_22Apr2020_final.pdf 10186CabozantinibHCC_SponsorFeedback_EC_22Apr2020_final.pdf 10186CabozantinibHCC_Combined ClinicianFeedback_EC_22Apr2020_final.pdf 10186CabozantinibHCC_COI CLF_EC_22Apr2020_final.pdf 10186CabozantinibHCC_Combined COI_EC_22Apr2020_final_Redacted.pdf	HCC	Reimburse with clinical criteria and/or conditions	Complete	Oct 16, 2019	Apr 22, 2020	PC0186-000
dupilumab	Dupixent	dupilumab	SR0636 Dupixent - CDEC Final Recommendation April 24, 2020 for posting.pdf sr0636-dupixent-clinical-review-report.pdf sr0636-dupixent-pharmacoeconomic-review-report.pdf SR0636 Dupixent - Patient Input Summary December 2019.pdf	atopic dermatitis	Reimburse with clinical criteria and/or conditions	Complete	Oct 22, 2019	Apr 22, 2020	SR0636-000
Pembrolizumab (Keytruda) for R...	Keytruda	Pembrolizumab	10185PembrolizumabRCC_fnRec_2020-03-31_ApprovedpERCChair_Post02Apr2020_final.pdf 10185PembrolizumabRCC_fnEGR_NOREDACT-ABBREV_Post02Apr2020_final.pdf 10185PembrolizumabRCC_fnCGR_REDACT_Post02Apr2020_final.pdf 10185PembrolizumabRCC_PAGFeedbackSummary_Post02Apr2020_final.pdf 10185PembrolizumabRCC_SponsorFeedback_Post24Mar2020_final.pdf 10185PembrolizumabRCC_ClinicianFeedback_CCOGUDAC_Post02Apr2020_final_Redacted.pdf 10185PembrolizumabRCC_PatientInput_KCC_COI_Post02Apr2020_final_Redacted.pdf 10185PembrolizumabRCC_Combined COIs_Post02Apr2020_final_Redacted.pdf Pembrolizumab (Keytruda) RCC – pERC Initial Recommendation	Renal Cell Carcinoma (RCC)	Reimburse with clinical criteria and/or conditions	Complete	Aug 2, 2019	Apr 2, 2020	PC0185-000
Gemtuzumab Ozogamicin (Mylotar...	Mylotarg	Gemtuzumab Ozogamicin	GemtuzumabOzogamicinMylotarg_AML10190ProvFunding.pdf 10190GemtuzumabOzogamacinAML_FnRec_2020-04-01_approvedbyChair_Post02Apr2020_final.pdf 10190GemtuzumabOzogamicinAML_fnEGR_NOREDACT-ABBREV_Post02Apr2020_final.pdf 10190GemtuzumabOzogamicinAML_fnCGR_NOREDACT_Post02Apr2020_final.pdf 10190GemtuzumabOzogamacinAML_inRec_ApprovedbyChair_Post_30Jan2020_final.pdf 10190GemtuzumabOzogamicinAML_PAGFeedbackSummary_Post02Apr2020_final.pdf 10190GemtuzumabOzogamicinAML_SponsorFeedback_Post02Apr2020_final.pdf 10190GemtuzumabOzogamicinAML_ClinicianFeedback_CCO_2020-02-13_Post02Apr2020_final_Redacted.pdf 10190GemtuzumabOzogamicinAML_Patient_COI_Post02Apr2020_final.pdf 10190GemtuzumabOzogamicinAML_Combined_COI_Post02Apr2020_final_Redacted.pdf	Acute Myeloid Leukemia (AML)	Reimburse	Complete	Aug 9, 2019	Apr 2, 2020	PC0190-000

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 401 - 425 of 602

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Sub Line	Status	Project Number
Rituximab for the Treatment of Myasthenia Gravis: A 2021 Update	Rituximab for the Treatment of Myasthenia Gravis: A 2021 Update	Apr 19, 2021	Rapid Review		RC1337-000
Urethral Inserts for the Management of Adult Male Urinary Incontinence	Urethral Inserts for the Management of Adult Male Urinary Incontinence	Apr 16, 2021	Rapid Review	Completed	RC1355-000
Pharmacological Interventions for Vaping Cessation	Pharmacological Interventions for Vaping Cessation	Apr 13, 2021	Summary with Critical Appraisal	Completed	RC1357-000
Models of Care for Chronic Pain: An Environmental Scan	Models of Care for Chronic Pain: An Environmental Scan Models of Care for Chronic Pain: Summarizing the Evidence	Apr 12, 2021	Environmental Scan	Completed	ES0350-000
Bupropion for Treatment Resistant Depression	RC1351 Bupropion for TRD Final.pdf	Apr 12, 2021	Summary with Critical Appraisal	Completed	RC1351-000
Lenses and Spectacles to Prevent Myopia Worsening in Children	RC1349 Myopia children Final.pdf	Apr 9, 2021	Summary with Critical Appraisal		RC1349-000
Interferon Gamma Release Assay for the Identification of Latent Tuberculosis Infection in Rural and Remote Settings	RC1341 IGRA vs TST upgrade Final.pdf	Apr 9, 2021	Summary with Critical Appraisal	Completed	RC1341-000
Flash Glucose Monitoring Systems in Pediatric Populations with Diabetes	RC1354 FGM for Pediatrics Final.pdf	Apr 6, 2021	Summary with Critical Appraisal	Completed	RC1354-000
COVID-19 Impact on Intimate Partner Violence and Child Maltreatment	COVID-19 Impact on Intimate Partner Violence and Child Maltreatment	Mar 30, 2021			CI0145-000
Point-of-Care Testing of International Normalized Ratios for People on Oral Anticoagulants: A Rapid Qualitative Review	Point-of-Care Testing of International Normalized Ratios for People on Oral Ant…	Mar 30, 2021	Summary with Critical Appraisal	Completed	RC1334-000
Treatment Sequences of Androgen Receptor Targeted Agents for Patients with Prostate Cancer	Summary With Critical Appraisal - Rapid Response Report	Mar 17, 2021	Summary with Critical Appraisal	Completed	RC1347-000
Remote Monitoring Programs for Cardiac Conditions in Canada		Mar 12, 2021	Environmental Scan	Completed	ES0345-000
Interventions to influence the use of antibiotics for acute upper respiratory tract infections	Interventions to influence the use of antibiotics for acute upper respiratory t…	Mar 12, 2021	Summary with Critical Appraisal		RC1332-000
Onabotulinum Toxin A for Spasticity Associated with Multiple Sclerosis	Onabotulinum Toxin A for Spasticity Associated with Multiple Sclerosis	Mar 11, 2021	Summary with Critical Appraisal		RC1340-000
Remote Monitoring Programs for Cardiac Conditions in Canada		Mar 11, 2021	Environmental Scan		ES0345-000
Stellate Ganglion Block for the Treatment of Post-Traumatic Stress Disorder, Depression, and Anxiety	RC1339 SGB PTSD Final.pdf	Mar 3, 2021	Summary with Critical Appraisal	Completed	RC1339-000
Codeine for Pain Related to Caesarean Section: A Review of Clinical Effectiveness	RC1326 Codeine for C-section Pain Final.pdf	Mar 3, 2021	Summary with Critical Appraisal	Completed	RC1326-000
Codeine for Acute Dental Pain and Acute Pain Related to Dental Procedures	RC1325-Codeine-Dental-Pain Final.pdf	Mar 3, 2021	Summary with Critical Appraisal	Completed	RC1325-000
Yttrium 90 Microspheres for Advanced, Recurrent, or Inoperable Hepatocellular Carcinoma: A Review of Clinical and Cost Effectiveness	RD0059 Y90 Microspheres Final.pdf	Mar 1, 2021	Rapid Review with Expert Input	Completed	RD0059-000
Patient Navigation Programs for People With Dementia	Patient Navigation Programs for People With Dementia	Feb 24, 2021	Summary with Critical Appraisal	Completed	RC1333-000
Rapid Testing for the Diagnosis of Pulmonary Tuberculosis and Rifampicin Resistance: A Review of Cost-Effectiveness	RC1328 GeneXpert Upgrade Econ Final.pdf	Feb 19, 2021	Summary with Critical Appraisal	Completed	RC1328-000
Incentives and Support Programs to Improve Adherence to Tuberculosis Treatment	RC1318 TB Treatment Adherence Final.pdf	Feb 18, 2021	Summary with Critical Appraisal	Completed	RC1318-000
Rituximab for the Treatment of Neuromyelitis Optica Spectrum Disorder	Rituximab for the Treatment of Neuromyelitis Optica Spectrum Disorder (Peer-re…	Feb 9, 2021	Peer-reviewed Summary with Critical Appraisal		RD0058-000
Gravity Drainage Versus Forced Suction Drainage for Patients With Excess Fluid in Pleural or Peritoneal Spaces	RC1327 Thoracentesis and Paracentesis Final.pdf	Feb 8, 2021	Summary with Critical Appraisal		RC1327-000
Workplace Electronic Health Promotion Campaigns for Tobacco Smoking Prevention or Cessation: A Review of Cost-Effectiveness	Workplace Electronic Health Promotion Campaigns for Tobacco Smoking Prevention …	Feb 2, 2021	Summary with Critical Appraisal	Completed	RC1335-000

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 110 of 110

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 27 of 27

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 401 - 425 of 2138

Please scroll or swipe to the right to view the full content.

Title	Description	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
nirmatrelvir/ritonavir		Recommendation and Reasons Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Stakeholder feedback on Draft Recommendation	Jul 9, 2024	Reimbursement Review		Complete	SR0808-000
Optimal installation of DI equipment			Jun 28, 2024	Health Technology Review		In Progress	CM0013-000
Appraisal of RWE submitted for health technology assessment			Jun 28, 2024	Health Technology Review		In Progress	MG0028-000
PET-CT Comparisons 2020-2024			Jun 28, 2024	Health Technology Review		In Progress	CM0006-000
Cystic Fibrosis			Jun 28, 2024	Health Technology Review		In Progress	HM0005-000
Natural Cycles App as Contraception			Jun 28, 2024	Horizon Scan	Health Technology Update	In Progress	EN0057-000
Newborn screening - Drugs for Rare Diseases Strategy			Jun 28, 2024	Health Technology Review	Technology Review	In Progress	HC0079-000
Methodology for Ethics Analysis in Pharmaceutical Reimbursement Reviews			Jun 28, 2024	Health Technology Review		In Progress	MG0027-000
Pharmaceutical Reviews Update — Issue 48			Jun 27, 2024	Reimbursement Review	Pharmaceutical Review Update
Endometrial Cancer		Final Report	Jun 27, 2024	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0045-000
NSCLC without actionable oncogenic alteration		Final Report	Jun 27, 2024	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0046-000
cannabidiol		Recommendation and Reasons Patient and Clinician Group Input Clinical and Pharmacoeconomic Combined Report Stakeholder feedback on Draft Recommendation	Jun 27, 2024	Reimbursement Review		Complete	SR0799-000
Choline Supplementation for Infants, Children, and Pregnant People		Choline Supplementation for Infants, Children, and Pregnant People	Jun 18, 2024	Health Technology Review	Rapid Review	Completed	RC1531-000
Interferons, Glatiramer Acetate, and Minocycline for Relapsing-Remitting Multiple Sclerosis and Clinically Isolated Syndrome		Interferons, Glatiramer Acetate, and Minocycline for Relapsing-Remitting Multiple Sclerosis and Clinically Isolated Syndrome	Jun 17, 2024	Health Technology Review	Rapid Review	Completed	RC1540-000
Nabilone for Chronic Non-Cancer Pain		Nabilone for Chronic Non-Cancer Pain	Jun 14, 2024	Health Technology Review	Rapid Review	Completed	RC1539-000
Infliximab for Immune Checkpoint Inhibitor Therapy-Related Toxicities		Infliximab for Immune Checkpoint Inhibitor Therapy-Related Toxicities	Jun 14, 2024	Health Technology Review	Rapid Review	Completed	RC1536-000
ravulizumab		Recommendation and Reasons Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Stakeholder feedback on Draft Recommendation	Jun 14, 2024	Reimbursement Review		Complete	SR0785-000
Minimum Retesting Intervals for Lab Tests	Canada’s Drug Agency partnered with Choosing Wisely Canada to host a multidisciplinary panel of experts to provide guidance on the minimum retesting intervals of laboratory tests that are commonly repeated in hospitals, health authorities, and community laboratories across the country.	Final Guidance Report Technology Review - Minimum Retesting Intervals for Lab Tests Lipase Quick Guide Hemoglobin A1C Quick Guide Thyroid Stimulating Hormone Quick Guide Serum Protein Electrophoresis Quick Guide Antinuclear Antibody Quick Guide	Jun 11, 2024	Health Technology Review	Technology Review	Completed	HC0078-000
treosulfan		Recommendation and Reasons Clinical, Pharmacoeconomic and Ethics combined Report Stakeholder feedback on Draft Recommendation	Jun 10, 2024	Reimbursement Review		Complete	PC0324-000
Anticytokine Therapy and Corticosteroids for Cytokine Release Syndrome and for Neurotoxicity Following T-Cell Engager or CAR T-Cell Therapy		Anticytokine Therapy and Corticosteroids for Cytokine Release Syndrome and for Neurotoxicity Following T-Cell Engager or CAR T-Cell Therapy	Jun 7, 2024	Health Technology Review	Rapid Review	Completed	RC1534-000
fidanacogene elaparvovec		Recommendation and Reasons Clinical, Pharmacoeconomic and Ethics combined Report Stakeholder feedback on Draft Recommendation	Jun 5, 2024	Reimbursement Review		Complete	SG0802-000
Virtual Medicine Wards and Hospital-at-Home Programs	Virtual wards, also known as hospital-at-home programs, support the provision of inpatient-level acute medical care in a patient’s home. Our Horizon Scan presents existing evaluations of virtual ward and hospital-at-home programs for early supported discharge.	Virtual Medicine Wards and Hospital-at-Home Programs	Jun 4, 2024	Horizon Scan	Health Technology Update	Completed	EN0056-000
Cutaneous Melanoma		Final Report Proposed Project Scope	Jun 4, 2024	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0042-000
Point-of-Care Tests for COVID-19 and Influenza in Canada		Point-of-Care Tests for COVID-19 and Influenza in Canada	Jun 4, 2024	Horizon Scan	Health Technology Update	Completed	EN0055-000
Bayesian Hierarchical Models of Basket Trials in the Context of Economic Evaluation		Bayesian Hierarchical Models of Basket Trials in the Context of Economic Evalua…	May 31, 2024	Health Technology Review	Technology Review	Completed	MH0020-000

Provisional Funding Algorithm

Displaying 76 - 81 of 81